358 patents
Page 16 of 18
Utility
Methods and Compositions for Modulating ALPHA-1-ANTITRYPSIN Expression
20 May 20
Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis.
Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
Filed: 25 Jun 19
Utility
Compositions and their uses directed to huntingtin
18 May 20
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Susan M. Freier
Filed: 6 Feb 18
Utility
Modulators of Complement Factor B
13 May 20
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
Filed: 11 Jun 19
Utility
Modulators of PNPLA3 Expression
6 May 20
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3.
Susan M. FREIER, Huynh-Hoa BUI
Filed: 17 Sep 19
Utility
Compositions and Methods for Modulating Growth Hormone Receptor Expression
22 Apr 20
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
Filed: 23 Jul 19
Utility
Modulation of Angiopoietin-like 3 Expression
15 Apr 20
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
Filed: 19 Dec 19
Utility
Cancer treatment
13 Apr 20
In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein.
Stanley T. Crooke, Mason Yamashita
Filed: 26 Nov 17
Utility
Modulation of huntingtin expression
13 Apr 20
Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal.
Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
Filed: 7 Feb 19
Utility
Method for solution phase detritylation of oligomeric compounds
13 Apr 20
Provided herein are methods for the synthesis of oligomeric compounds wherein removal of the 5′-terminal trityl group is performed at reduced temperature and lower pH relative to standard methods.
Dana Chreng
Filed: 26 Jul 17
Utility
Modulation of Apolipoprotein C-iii (Apociii) Expression In Lipodystrophy Populations
25 Mar 20
Andres Digenio
Filed: 30 Jul 19
Utility
Compositions for Modulating Ataxin 2 Expression
18 Mar 20
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression.
Susan M. Freier
Filed: 16 Apr 19
Utility
Compositions and methods for modulation nucleic acids through nonsense mediated decay
16 Mar 20
Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid.
Amanda Ward, Frank Rigo
Filed: 20 Apr 14
Utility
Compositions and Methods for Modulating MECP2 Expression
11 Mar 20
Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression.
Susan M. Freier, Huda Y. Zoghbi, Ezequiel Sztainberg
Filed: 7 Aug 19
Utility
Allele Specific Modulators of P23H Rhodopsin
4 Mar 20
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject.
Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
Filed: 27 Aug 19
Utility
Methods for monitoring C9ORF72 expression
2 Mar 20
Disclosed herein are methods for monitoring expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors.
C. Frank Bennett, Susan M. Freier, Jeffrey D. Rothstein, Christopher Donnelly, Rita G. Sattler
Filed: 14 Oct 13
Utility
Modulation of DYRK1B expression
2 Mar 20
Provided herein are methods, compounds, and compositions for reducing expression of DYRKIB in an animal.
Brett P. Monia, Shuling Guo, Susan F. Murray
Filed: 15 Mar 17
Utility
Conjugated antisense compounds and their use
24 Feb 20
Provided herein are oligomeric compounds with conjugate groups.
Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
Filed: 20 May 15
Utility
Modulation of Apolipoprotein Ciii (Apociii) Expression
19 Feb 20
Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal.
Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
Filed: 27 May 19
Utility
Selective Antisense Compounds and Uses Thereof
19 Feb 20
The present disclosure provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 28 Mar 19
Utility
Compositions and Methods for Modulating PKK Expression
19 Feb 20
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Filed: 24 Mar 19